Zhuzhou Yuancheng Hezhong Technology Development Co., Ltd.

Zhuzhou Yuancheng Hezhong Technology Development Co., Ltd.

You are here: HomeProductsRaloxifene hydrochloride

Contact us

  • Company Name: Zhuzhou Yuancheng Hezhong Technology Development Co., Ltd.
  • Country/region: China
  • Contact Person: Ms.Vicky Yin
  • Tel: 86-181-88938010
  • Email:

Raloxifene hydrochloride

  • CAS No:82640-04-8 [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-<br />ylethoxy)phenyl]methanone
    Molecular Structure

    Detailed Description

    Raloxifene hydrochloride

    Alias: RALOXIFENE HCL; ly156758; KEOXIFENE;KEOXIFENE HYDROCHLORIDE;LY 139481;AKOS 92138

    Product Details:
    Place of Origin: China
    Certification: ISO9001
    Brand:YuanCheng

    Payment & Shipping Terms:

    Minimum Order Quantity:1kg
    Supply Ability:500kg/month
    Delivery Time:within 24 hours after payment

    Payment Terms:Western Union, MoneyGram, T/T
    Package:25kg/cardboad drum
    Appearance:light yellow

    Product Description:
    CAS: 82640-04-8
    M.F.: C28H28ClNO4S
    M.W. :510.04
    Purity:99.8%
    M.P.: 250-253°C



    EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds

    The chemical designation is methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, hydrochloride. Raloxifene hydrochloride (HCl) has the empirical formula C28H27NO4S.HCl, which corresponds to a molecular weight of 510.05. Raloxifene HCl is an off-white to pale-yellow solid that is very slightly soluble in water.

    EVISTA (raloxifene) is supplied in a tablet dosage form for oral administration. Each EVISTA tablet contains 60 mg of raloxifene HCl, which is the molar equivalent of 55.71 mg of free base. Inactive ingredients include anhydrous lactose, carnauba wax, crospovidone, FD&C Blue No. 2 aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, modified pharmaceutical glaze, polyethylene glycol, polysorbate 80, povidone, propylene glycol, and titanium dioxide.

    Usage:
    Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.
    in 2006, the National Cancer Institute announced that raloxifene was as effective as tamoxifen in reducing the incidence of breast cancer in postmenopausal women at increased risk,

    ychz01(at)yccreate dot com
  • Raloxifene hydrochloride
  • Raloxifene hydrochloride